)
Visual24 Oct 2025
The rise of Alphabet
Neumora Therapeutics (NMRA) investor relations material
Neumora Therapeutics R&D Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.R&D Day 2025 summary27 Oct, 2025
Pipeline overview and program updates
Advancing a broad neuroscience pipeline with seven programs targeting obesity, schizophrenia, Alzheimer's agitation, MDD, Parkinson's, and ALS, spanning preclinical to Phase 3 stages.
NMRA-215, an oral NLRP3 inhibitor, showed up to 19% weight loss as monotherapy and 26% in combination with semaglutide in preclinical models.
Key programs include Navacaprant (KOR antagonist), NMRA-511 (V1aR antagonist), NMRA-861 and NMRA-898 (M4 modulators), and NMRA-215 (NLRP3 inhibitor), with multiple clinical study initiations and data readouts expected in the next 12 months.
The pipeline emphasizes differentiated, best-in-class pharmacology and brain-penetrant therapies for prevalent, underserved diseases.
Clinical trial data and development milestones
NMRA-215 demonstrated class-leading weight loss and preserved lean mass with improved cardiometabolic biomarkers in preclinical models; Phase 1 studies are planned for Q1 2026.
NMRA-511 Phase 1b study in Alzheimer's agitation is ongoing, with top-line data expected by year-end 2025; prior studies showed safety and tolerability.
Navacaprant is in Phase 3 KOASTAL program for MDD, with KOASTAL-3 topline data expected 1Q26 and KOASTAL-2 in 2Q26.
M4 PAM franchise (NMRA-861, NMRA-898) is progressing toward clinical studies, with updates expected by mid-2026.
Additional data for NMRA-215 will be presented during a virtual R&D day on October 27, 2025.
R&D strategy and innovation priorities
Focus on advancing brain-penetrant, highly selective molecules with best-in-class potential and novel mechanisms of action for CNS and metabolic diseases.
Emphasis on programs with high translational potential, leveraging robust preclinical data and developing both monotherapy and combination regimens.
Strategy includes selectivity for key targets (NLRP3, V1aR, M4R, KOR) and exploring NMRA-215 for Parkinson's disease.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Neumora Therapeutics earnings date
Q3 202511 Nov, 2025
Next Neumora Therapeutics earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Neumora Therapeutics Inc., known as NMRA, is a clinical-stage biopharmaceutical company focused on the development of therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Founded in 2019 and formerly known as RBNC Therapeutics, Inc., Neumora aims to redefine neuroscience drug development by integrating data science with neuroscience to pioneer precision medicines for complex brain diseases. The company's pipeline includes various programs at different stages of clinical trials targeting diseases such as major depressive disorder, agitation associated with dementia due to Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Parkinson's disease, among others. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage